|
Bioglan is selling its GenPlus generics telesales business in Waterlooville to Ethercorp for a nominal sum, in order to focus on dermatology and the development of the Biosphere drug delivery system. 05-Dec-2001 Bioglan, the pharmaceuticals company, has put itself up for sale after being forced to restate its interim results, and has already received a number of preliminary offers. 20-Nov-2001 Bioglan is planning a major cost-cutting programme following the collapse of a £527m deal to acquire Bristol Myers Squibb's skincare business. 19-Oct-2001 Bioglan is in negotiations to acquire the skin products business of Bristol-Myers Squibb of the US for £493m. 20-Jul-2001 Bioglan is planning to buy or set up new companies in Italy and Spain later this year, as part of a strategy to expand its speciality pharmaceuticals business across Europe. 20-Apr-2001 Bioglan has acquired the skincare business of Hexal of Germany for £16m, and is now looking to more than double the size of its German salesforce. 04-Jan-2001 Bioglan Pharma has acquired the remaining 50% of CS Laboratories, the French pharmaceutical company, and is now looking to further expand its activities in the US and Europe. 29-Sep-2000 Bioglan Pharma is to buy a 19% stake in Winston Laboratories, the US developer of pain management products, for £15m. 17-Dec-1999 Bioglan Pharma is to raise £23m in a share offer in order to help fund the purchase of a range of dermatological products from Medicis Pharmaceutical of the US. 30-Jun-1999 Bioglan Pharma is looking to expand its drug delivery business in the US and Europe by building up a sales and distribution network and by acquiring new products. 29-Apr-1999 Bioglan Pharma is buying a portfolio of dermatological products from Medicis Pharmaceutical for £6.7m, as part of a strategy to expand its presence in the US. 18-Mar-1999 Bioglan Pharma is planning to raise £18m in a flotation, and some of the proceeds will be used to finance acquisitions in dermatology and drug delivery. 11-Dec-1998 Bioglan Holdings is planning to raise £20m in a flotation in order to reduce debt, fund expansion into the US and Europe, and help it make acquisitions in dermatology and drug delivery. 09-Nov-1998
|